Open AccessP933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D‐RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY
Author(s) -
Spencer A.,
Moreau P.,
Mateos M.V.,
Goldschmidt H.,
Suzuki K.,
Levin M.D.,
Sonneveld P.,
Yoon S.S.,
Usmani S. Z.,
Weisel K.,
Reece D.,
Ahmadi T.,
Pei H.,
Garvin Mayo W.,
Gai X.,
Carey J.,
Carson R.,
Dimopoulos M. A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846600.20422.ca
Subject(s) - medicine , lenalidomide , daratumumab , clinical endpoint , oncology , dexamethasone , subgroup analysis , clinical trial , confidence interval